We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR... Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. Show more
Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta...
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Companyโs President and CEO Gilmore OโNeill...
Focus on in vivo CRISPR-edited medicines based on Editas researchersโ recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter...
Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing...
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -2.83687943262 | 1.41 | 1.48 | 1.32 | 1856971 | 1.38778948 | CS |
4 | 0.065 | 4.98084291188 | 1.305 | 1.57 | 1.12 | 2415838 | 1.32240388 | CS |
12 | -1.785 | -56.5768621236 | 3.155 | 3.375 | 1.12 | 2653096 | 1.73481658 | CS |
26 | -4.02 | -74.5825602968 | 5.39 | 5.705 | 1.12 | 2235927 | 2.64634622 | CS |
52 | -5.88 | -81.1034482759 | 7.25 | 11.58 | 1.12 | 2111648 | 4.45749371 | CS |
156 | -16.14 | -92.175899486 | 17.51 | 21.595 | 1.12 | 1883291 | 8.66658979 | CS |
260 | -25.4 | -94.8823309675 | 26.77 | 99.95 | 1.12 | 1754062 | 21.47333066 | CS |
Symbol | Price | Vol. |
---|---|---|
CLEUChina Liberal Education Holdings Ltd | US$ 0.1737 (17.21%) | 8.39M |
KITTNauticus Robotics Inc | US$ 2.57 (64.74%) | 5.34M |
TDTHTrident Digital Tech Holdings Ltd | US$ 1.92 (102.11%) | 1.52M |
BHATBlue Hat Interactive Entertainment Technology | US$ 0.035 (-12.50%) | 1.03M |
RIMEAlgorhythm Holdings Inc | US$ 0.0256 (4.92%) | 1.02M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions